Skip to main content
. 2016 Oct 25;7(48):78859–78871. doi: 10.18632/oncotarget.12889

Figure 5. NID2 suppresses important signaling pathways in cancer.

Figure 5

(A) Phosphorylation study of NID2-expressing cells using the Human Phospho-Kinase Antibody Array. Reduced phosphorylation of (1) FAK (Y397), (3) STAT1 (Y701), (4) Akt (T308), (5) STAT4 (Y693), (6) RSK1/2/3 (S380/S386/S377), and (7) PLCγ (Y783), and increased phosphorylation of (2) ERK1/2 (T202/Y204, T185/Y187) in the NID2-expressing cells was observed. The bar chart shows the relative quantification of the array data, normalized to VA control (*p < 0.05). Blue arrows indicated significant changes that were further validated using Western blot. (B) Re-expression of NID2 in HONE1 and KYSE30 cell lines resulted in reduced phosphorylation levels of FAK (Y397/Y925) and PLCγ (Y783), as shown by representative Western blot images. (C) The levels of phosphorylated EGFR at five tyrosine sites (Y992/Y1068/Y1086/Y1148/Y1173) were decreased by the re-expression of NID2 in both HONE1 and KYSE30. Downstream Akt pathways were also suppressed by NID2, as shown by the reduced phosphorylation level of Akt (T308/S473). Numbers at the bottom of each band represent the relative quantification of the protein level, normalized to the VA control.